Business
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery - CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data on the discovery of a novel cell surface receptor identified as a binding receptor for a family of Voyager’s next-generation TRACER AAV capsids. This receptor is expressed in human central nervous system (CNS) and brain endothelial cells, increasing the potential for the associated capsid family to translate into humans. In addition, Voyager presented preclinical data demonstrating the potential for ultra-low dosing with a separate next-generation TRACER capsid family. These and other data were presented by Voyager at the European Society of Gene & Cell Therapy (ESGCT) 29th Annual Congress in Edinburgh, Scotland. “Our discovery of a binding receptor for one of our capsid families, along with the data showing the receptor to be highly conserved across multiple species including humans, increases our confidence that the preclinical data on gene therapies utilizing this capsid family may translate in human clinical trials,” said Alfred Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “In the longer term, this receptor could enable reverse engineering to further enhance our capsid discovery platform. In addition, we have begun experiments to explore whether we may be able to leverage this receptor to enable the delivery of modalities such as proteins and oligonucleotides across the blood-brain barrier – which, if successful, could constitute a new platform for CNS drug development.” Details of Voyager’s presentations at ESGCT are as follows: Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with Enhanced Brain Tropism in Non-Human Primates and Mice (Poster #P024) Voyager has identified a highly conserved membrane protein as the primary cell surface receptor responsible for improved CNS biodistribution for one of Voyager’s novel TRACER capsid families.This capsid family has been demonstrated to cross the blood-brain barrier (BBB) ...